Kamada: Earnings Expansion Cycle With Embedded Margin Of Safety

Kamada Ltd. (KMDA) is rated a buy, showcasing strong H1 financial results with 11% YoY revenue growth to $88.8mm and a 35% increase in adjusted EBITDA to $22.5mm, prompting raised FY'25 guidance. The company demonstrates significant operating leverage and robust cash generation, yielding 9% TTM FCF, while strategically advancing its Phase 3 InnovAATe trial and securing FDA approval for its Houston plasma center, which enhances vertical integration. Despite minor Q2 gross margin compression and working capital fluctuations, the analyst maintains a bullish outlook, citing KMDA's attractive valuation at 14x forward EBIT and an estimated 18% upside to a $474mm market value.

Analysis

Kamada Ltd. is demonstrating a compelling financial and operational turnaround, marked by strong performance in the first half of the year. The company reported an 11% year-over-year revenue increase to $88.8 million and a significant 35% rise in adjusted EBITDA to $22.5 million, translating to a robust 25% EBITDA margin. This performance prompted management to raise its full-year 2025 adjusted EBITDA guidance to a range of $40-44 million. A key driver of this profitability is substantial operating leverage, with each dollar of new sales generating between $3 and $5 of incremental operating profit. While Q2 gross margin saw a slight compression to 42% from 45% year-over-year due to a strategic product mix shift, the company's tight management of operating expenses reinforces long-term margin durability. The business is highly cash-generative, evidenced by a trailing-twelve-month free cash flow yield of 9% and a greater than 1-to-1 conversion of net operating profit to FCF. Strategically, Kamada is advancing its growth pillars with the FDA approval of its Houston plasma collection center, which adds vertical integration and an estimated $8-10 million in revenue potential, and the progression of its Phase 3 InnovAATe trial, with an interim analysis expected by year-end. The market appears to be recognizing this value creation, as the stock trades at 14x forward EBIT with an analyst-projected 18% upside to a $474 million valuation, suggesting a solid margin of safety.

Key Decisions for Investors

• Given the strong earnings growth, raised guidance, and a 9% free cash flow yield, investors may view the current valuation of 14x forward EBIT as an attractive entry point for a cash-generative biotech firm.
• Key catalysts to monitor for potential share price appreciation are the year-end interim analysis of the Phase 3 InnovAATe trial and the successful operational ramp-up of the new Houston plasma center to its projected $8-10 million revenue capacity.
• While the outlook is bullish, it is prudent to monitor gross margin trends for further compression due to product mix shifts and track working capital movements, as H1 operating cash flow declined due to inventory builds.